Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 28;27:70. doi: 10.1186/s12929-020-00662-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Comparison of the immunogenicity of HBV core antigen and that of HBV X protein. a-c HBV carrier mice (N = 3) received vaccination with 3.125 μg of rHBc or rHBx supplemented with 0.625 μg of CpG-ODN on days 0, 7 and 14. Mouse serum was sampled on days 0, 7, 14, 21 and 35. (a) Serum HBs titers were determined. b Serum anti-HBs antibody titer on day 35. c Serum anti-HBc antibody titer on day 35. Lower values represent higher antibody production because the anti-HBc assay is a competition assay. d HBV carrier mice (N = 3 ~ 4) received vaccination with 6.25 μg of rHBc or rHBx supplemented with 1.25 μg of CpG-ODN on days 0, 7, 14 and 22. Mice were boosted once with the same dose 7 days before splenocyte isolation. Splenocytes were separately stimulated with HBx-, HBs-, or HBc-derived 15-mer overlapping peptide pool and subjected to an IFN-γ ELISpot assay. The result was normalized to the spot counts per million cells. LoD, limit of detection; SFCs, spot-forming cells